This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Frank Jaschinski, Ph.D.
Chief Scientific Officer at Secarna Pharmaceuticals


As CSO of Secarna Pharmaceuticals, Frank Jaschinski is responsible for the scientific progress of Secarna’s programms. After receiving his PhD in biochemistry at the University of Zürich in 2001, he entered The Genetics Company, a biotech startup in Switzerland. In 2006 he joined the department of preclinical research & development of Antisense Pharma. During the transition of Antisense Pharma into Isarna Therapeutics, he was responsible for the generation of a new pipeline of antisense oligonucleotides against TGF-beta. In 2015 he joined Secarna Pharmaceuticals as Chief Science Officer.

Agenda Sessions

  • Examples of Antisense Oligonucleotides that Target the Immunosuppressive Tumor Microenvironment for Treatment of Cancer